ZEPATIER is a prescription medicine used with or without ribavirin to treat chronic (long-lasting) hepatitis C (hep C) genotypes 1 or 4 infection in adults. See important information below including the risk of hepatitis B virus reactivation.

 

Request MoreInformation

Request MoreInformation

Models

Want more information to see if you could start writing your next chapter with ZEPATIER?

Sign up now and receive free information on ZEPATIER including:

 

Helpful tips on the treatment of
your hep C.

 

Possible financial
assistance options.

The C Ahead Patient Support
Program
gives you support by e-mails,
as well as text reminders and/or a mobile app, if you would like to use those as well.

 
Please complete the form below.
*Required fields
* Are you 18 years of age or older?
YES
NO
You must be 18 years of age or older to sign up
* Are you currently being treated with ZEPATIER?
YES
NO
Merck's Privacy Commitment

The information you provide will be available to the Merck & Co., Inc., family of companies (collectively, “Merck”) and others working on behalf of Merck, to provide the information and services you request. Personal information about you will not otherwise be disclosed for marketing purposes without your permission. Merck reviews personal information and nonidentifiable information not only to provide the requested information and services but also to develop and offer additional services and communications that we believe our customers might find of interest. Merck also may use personal information to audit its resources for compliance and security purposes. For more information about how Merck protects personal information about you, please read the Internet Privacy Policy and Privacy Commitment for US patients, consumers, and caregivers.

 
 
* First name:
* Last name:
* E-mail address:
* Address 1:
Address 2:
* Zip code:
* City:
* State:
Optional:

Supported Carriers: The Hep C Text Support Program is supported by all major carriers. Message and data rates may apply. Requires text-enabled handset.

Cost: There is no cost from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., to receive these text messages; however, message and data rates may apply. Charges are dependent on your service plan, which may include fees from your carrier to send and receive text messages.

Message Frequency: You may cancel your subscription at any time by texting STOP to 69866. You can also get info directly on your phone by texting HELP to 69866. You acknowledge you have read and agree to the Terms and Conditions of this program. Subscribing to the Hep C Text Support Program is not required to obtain any product or service.

By providing your name, address, and other personal information above and clicking the "submit" button below you agree to permit Merck and others working on behalf of Merck to use this information to provide you with information, resources, services and communications about ZEPATIER, C Ahead, hepatitis C and related treatment options via e-mail, or as you have otherwise indicated which may include text messages if you have chosen. Additionally, your information may be used for market research purposes.

At any time, you can request a copy of this permission and that personal information about you be removed from the Merck contact list for ZEPATIER or hepatitis C medications by calling 1-888-776-8364. Unless you change this selection sooner, your permission will expire 1 year after Merck no longer promotes ZEPATIER and the C Ahead Patient Support Program.

By clicking "submit" I am signing this form. I agree that my information may be used as described above, as well as for market research purposes.

SUBMIT
Merck's Privacy Commitment

The information you provide will be available to the Merck & Co., Inc., family of companies (collectively, “Merck”) and others working on behalf of Merck, to provide the information and services you request. Personal information about you will not otherwise be disclosed for marketing purposes without your permission. Merck reviews personal information and nonidentifiable information not only to provide the requested information and services but also to develop and offer additional services and communications that we believe our customers might find of interest. Merck also may use personal information to audit its resources for compliance and security purposes. For more information about how Merck protects personal information about you, please read the Internet Privacy Policy and Privacy Commitment for US patients, consumers, and caregivers.



Please orient your device to the portrait position to return to the site

 

Important Safety Information

Before starting treatment with ZEPATIER® (elbasvir and grazoprevir), your health care provider will do blood tests to check for hepatitis B virus infection. If you have ever had hepatitis B virus infection, the hepatitis B virus could become active again during or after treatment of hep C virus infection with ZEPATIER. This is called hepatitis B virus reactivation, and it may cause serious liver problems including liver failure and death. Your health care provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop taking ZEPATIER.

Important Safety Information continued below

ZEPATIER is not for people with certain liver problems. Before taking ZEPATIER, tell your health care provider about all of your medical conditions, including if you have ever had hepatitis B virus infection or have liver problems other than hep C. Also tell your health care provider if you have ever taken any medicine for hep C, have HIV, or have had or are waiting for a liver transplant.

If you are nursing, pregnant, or trying to get pregnant, tell your health care provider. It is not known if ZEPATIER will harm your unborn baby or pass to your baby through breast milk. If you take ZEPATIER with ribavirin, be sure you read the Medication Guide for ribavirin, especially the important pregnancy, contraception, and infertility information.

Tell your health care provider about all of the medicines you take. ZEPATIER may affect how other medicines work, and other medicines may affect how ZEPATIER works. Some medicines cannot be taken with ZEPATIER. Your health care provider can tell you if it is safe to take ZEPATIER with other medicines.

ZEPATIER may cause increases in your liver-related blood tests, which could be a sign of serious liver problems. Your health care provider will do blood tests to check your liver before and during treatment with ZEPATIER. Tell your health care provider right away if you get any of the following symptoms or if they get worse during treatment with ZEPATIER: loss of appetite, nausea and vomiting, feeling tired or weak, yellowing of your skin or eyes, or color changes in your stool.

In clinical studies, common side effects of ZEPATIER included: feeling tired, headache, and nausea. When ZEPATIER was taken with ribavirin, common side effects also included low red blood cell counts (called anemia).

What is ZEPATIER?

ZEPATIER is a prescription medicine used to treat chronic (long-lasting) hepatitis C (hep C) genotypes 1 or 4 infection in adults. ZEPATIER may sometimes be given with another medicine called ribavirin.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call
1-800-FDA-1088.

Before taking ZEPATIER® (elbasvir and grazoprevir), please read the accompanying Patient Information, including information about the risk of the hepatitis B virus (HBV) becoming active again in patients who have ever had HBV infection, and discuss it with your doctor. The Prescribing Information also is available.

Questions about ZEPATIER?
Call 844-ZEPATIER (844-937-2843)
for more information.

Important Safety Information continued below